SA520412443B1 - تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول - Google Patents

تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول

Info

Publication number
SA520412443B1
SA520412443B1 SA520412443A SA520412443A SA520412443B1 SA 520412443 B1 SA520412443 B1 SA 520412443B1 SA 520412443 A SA520412443 A SA 520412443A SA 520412443 A SA520412443 A SA 520412443A SA 520412443 B1 SA520412443 B1 SA 520412443B1
Authority
SA
Saudi Arabia
Prior art keywords
once daily
daily administration
ophthalmic compositions
benzimidazole compounds
compositions once
Prior art date
Application number
SA520412443A
Other languages
English (en)
Inventor
جونزالو جوروستيزا آنا
زازبي اركي ارتورو
فيرنانديـز فيريرو انزو
موران بولادورا بابلو
تاتو سيرديراس بالوما
جونزاليـز جارسيا تانيا
هيرنانديـز هيريرو جونزالو
خافير اوتيرو إسبينار فرانسيسكو
دياز تومي فيكتوريا
فيرنانديـز هيرناندو نيفيس
Original Assignee
.فايس فارما، اس. ايه
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by .فايس فارما، اس. ايه filed Critical .فايس فارما، اس. ايه
Publication of SA520412443B1 publication Critical patent/SA520412443B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلانية مائية للعين ophthalmic pharmaceutical تشتمل على: أ- على الأقل 0.4% بالوزن/الحجم من بيلاستين bilastine له الصيغة: أو ملح مقبول صيدلانيًا أو ذوابة منه، حيث تتم إذابة ملح بيلاستين bilastine أو ذوابة منه بالكامل في التركيبة الصيدلانية؛ ب- على الأقل β–سيكلو دكسترين β-cyclodextrin ؛ ج- على الأقل عامل تكوين الجل القابل للذوبان في الماء مقبول صيدلانيًا، وحيث يتراوح الرقم الهيدروجيني pH بين 4 و9. واستخدامه في علاج و/أو الوقاية من الحالات التي يتوسطها مستقبل الهستامين histamine H1، على سبيل المثال، اضطرابات أو أمراض الحساسية allergic disorders or diseases . يتعلق الاختراع الحالي بعلاج و/أو بالوقاية من التهاب الملتحمة التحساسي allergic conjunctivitis . شكل 1.
SA520412443A 2018-01-18 2020-07-15 تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول SA520412443B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382021 2018-01-18

Publications (1)

Publication Number Publication Date
SA520412443B1 true SA520412443B1 (ar) 2022-09-01

Family

ID=61017875

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520412443A SA520412443B1 (ar) 2018-01-18 2020-07-15 تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول

Country Status (26)

Country Link
US (1) US20210128544A1 (ar)
EP (2) EP3740191B1 (ar)
JP (1) JP7309729B2 (ar)
KR (1) KR20200111727A (ar)
CN (1) CN111727035B (ar)
AR (1) AR114216A1 (ar)
AU (1) AU2019209214B2 (ar)
BR (1) BR112020014265A2 (ar)
CA (1) CA3088740A1 (ar)
CL (1) CL2020001895A1 (ar)
CO (1) CO2020009992A2 (ar)
CY (1) CY1124270T1 (ar)
DK (1) DK3740191T3 (ar)
EA (1) EA202091725A1 (ar)
ES (1) ES2878107T3 (ar)
HR (1) HRP20211037T1 (ar)
HU (1) HUE054594T2 (ar)
LT (1) LT3740191T (ar)
MA (1) MA51612B1 (ar)
MX (1) MX2020007692A (ar)
PL (1) PL3740191T3 (ar)
PT (1) PT3740191T (ar)
SA (1) SA520412443B1 (ar)
SI (1) SI3740191T1 (ar)
UY (1) UY38055A (ar)
WO (1) WO2019141563A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023156559A1 (en) 2022-02-17 2023-08-24 Faes Farma, S.A. Bilastine composition for once-daily parenteral administration
CN115970066A (zh) * 2022-12-29 2023-04-18 成都爱睿康乐医疗器械有限公司 基于主客体相互作用的载药纳米凝胶生物润滑剂及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
JP3527256B2 (ja) 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
DE60216641T2 (de) 2002-04-19 2007-09-27 Faes Farma S.A. Polymorph von 4-ä2-ä4-ä1-(2-ethoxyethyl)-1h-benzimidazol-2-ylü-1-piperidinylüethylü-alpha, alpha-dimethylbenzolessigsäure
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US7247623B2 (en) 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
JP5292277B2 (ja) 2006-03-31 2013-09-18 ビスタコン・フアーマシユーチカルズ・エルエルシー 眼アレルギーの処置
CN101460176B (zh) * 2006-03-31 2012-11-28 维斯塔肯药品有限责任公司 眼变态反应治疗
EP2173169B1 (en) 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
WO2010107525A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN103110575B (zh) * 2013-03-07 2014-11-05 宁夏康亚药业有限公司 一种美洛昔康滴眼液及其制备方法和应用
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents

Also Published As

Publication number Publication date
CA3088740A1 (en) 2019-07-25
CY1124270T1 (el) 2022-07-22
AR114216A1 (es) 2020-08-05
AU2019209214A1 (en) 2020-08-13
BR112020014265A2 (pt) 2020-12-08
DK3740191T3 (da) 2021-06-07
EP3740191B1 (en) 2021-04-28
TW201932110A (zh) 2019-08-16
AU2019209214B2 (en) 2023-11-23
US20210128544A1 (en) 2021-05-06
MA51612A (fr) 2020-11-25
MX2020007692A (es) 2020-09-14
SI3740191T1 (sl) 2021-09-30
EP3740191A1 (en) 2020-11-25
UY38055A (es) 2019-08-30
CO2020009992A2 (es) 2021-01-18
JP7309729B2 (ja) 2023-07-18
PT3740191T (pt) 2021-07-09
PL3740191T3 (pl) 2021-11-29
KR20200111727A (ko) 2020-09-29
CN111727035A (zh) 2020-09-29
HRP20211037T1 (hr) 2021-10-01
HUE054594T2 (hu) 2021-09-28
EA202091725A1 (ru) 2020-10-12
JP2021511317A (ja) 2021-05-06
EP3915539A1 (en) 2021-12-01
LT3740191T (lt) 2021-08-10
MA51612B1 (fr) 2021-06-30
CN111727035B (zh) 2024-05-28
WO2019141563A1 (en) 2019-07-25
CL2020001895A1 (es) 2020-12-04
ES2878107T3 (es) 2021-11-18

Similar Documents

Publication Publication Date Title
MX2021004431A (es) Procesos novedosos.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011196A (es) Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida.
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
MX2020001403A (es) Nuevos derivados de quinolina.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
SA520412443B1 (ar) تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول
MX2022006736A (es) Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
MX2020011873A (es) Nuevos derivados de quinolina.
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
MX2021013135A (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
MX2017008495A (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
WO2020128816A3 (en) Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
AU2017261303A1 (en) Ophthalmic compositions
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
EA202090965A1 (ru) Водные композиции биластина
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.